A New Jersey judge dismissed allegations Tuesday from users of generic versions of the heartburn medication Reglan that the drug's brand-name manufacturers, including Wyeth LLC, misrepresented its risks, finding the U.S. Supreme Court's Mensing decision did not address brand-name companies' duty to generics users.


To read this complete article visit Law360.